2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Emerging Technologies, Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, B Cell Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2281 Second CAR T-cell infusion after prior CAR T-cell failure in multiple myeloma

Jianlin Hu, Ning An2, Yuhan Bao, MBBS3, Qiuxia Yu4, Xinran Wang5, Yuying Wang6, Yang Gao7, Shangyun Sun8, Peiling Zhang9, Di Wang10, Chunrui Li, MD,PhD11
1 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
6 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
7 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
8 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
9 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
10 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
11 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Background: Relapse or progression after CAR T-cell therapy remains a major challenge in relapsed/refractory multiple myeloma (RRMM). Evidence to guide a second CAR T-cell infusion is limited, particularly regarding target selection and whether in vivo expansion relates to benefit or toxicity. We evaluated outcomes, safety, and expansion after a second CAR T-cell infusion following prior CAR T-cell failure.

Methods: This single-center retrospective study included 23 patients with RRMM who received a second CAR T-cell infusion between January 2018 and April 2026. Products targeted BCMA, GPRC5D, or both. Responses were assessed by International Myeloma Working Group criteria. Progression-free survival after the second infusion (PFS2) was measured from infusion to progression or death, overall survival (OS) from infusion to death, and duration of response (DOR) from first partial response or better (≥PR) to progression or death. Time-to-event outcomes were estimated by Kaplan–Meier methods. Expansion was summarized by peak transgene copy number (Cmax), time to peak expansion (Tmax), and area under the curve from day 0 to 28 (AUC0–28). Comparative analyses were exploratory.

Results: Median age at the second infusion was 54.6 years (range, 39.8–69.8), 14 patients (60.9%) were male, and the median number of prior lines was 5 (range, 4–11). Nine patients (39.1%) had extramedullary disease. The median interval between infusions was 16.2 months. Twelve patients received a same-target second infusion, 8 received a target-switched infusion, and target status was unavailable in 3.

At the July 1, 2026 cutoff, median follow-up was 46.4 months (95% CI, 35.1–57.6). Among 20 response-evaluable patients, the overall response rate was 80.0%: 6 (30.0%) achieved complete or stringent complete response (CR/sCR), 3 (15.0%) very good partial response, and 7 (35.0%) partial response. Median DOR was 9.3 months (95% CI, 7.81–10.79), median PFS2 was 7.2 months (95% CI, 3.4–28.8), and median OS was 32.5 months (95% CI, 12.4–not reached).

Among 16 patients evaluable after both infusions, 7 (43.8%) achieved an equal or deeper response with the second infusion. CR/sCR occurred in 5 of 12 patients receiving a same-target second infusion and none of 8 receiving a target-switched infusion (P=0.029), although no significant association was observed between target strategy and PFS2 or OS.

Among patients with expansion data, Cmax and AUC0–28 were higher in responders than in nonresponders (P=0.036 and P=0.044). Higher Cmax was also associated with early grade ≥3 thrombocytopenia and anemia (both P=0.025). Cmax and AUC0–28 were not associated with PFS2 or OS, whereas later Tmax was associated with a lower risk of progression or death (HR per day, 0.893; 95% CI, 0.808–0.988; P=0.028). In the small paired subset, second-to-first changes in expansion were not associated with response depth or PFS2.

Cytokine release syndrome (CRS) occurred in 21 patients (91.3%), including grade ≥3 CRS in 3 (13.0%); no immune effector cell-associated neurotoxicity syndrome occurred. Early grade ≥3 neutropenia, thrombocytopenia, and anemia occurred in 22 (95.7%), 19 (82.6%), and 19 patients (82.6%), respectively. Infections occurred in 17 patients (73.9%), with no treatment-related deaths.

Conclusions: A second CAR T-cell infusion produced meaningful responses in selected patients after prior CAR T-cell failure. Same-target retreatment was associated with more frequent deep responses but not longer PFS2 or OS. Greater early expansion was associated with both response and severe cytopenias, while later peak expansion was associated with longer PFS2. Larger prospective studies are needed to confirm these associations.
Jianlin Hu: No relevant conflicts of interest to declare.